Background
==========

The majority of adult patients with central diabetes insipidus (DI) have abnormalities on pituitary magnetic resonance imaging (MRI), with loss of the posterior pituitary high-intensity signal and pituitary stalk thickening being most common ([@bib1]). The differential diagnoses for infundibulum lesions is broad, and thorough investigations are required to identify a cause, which may be treated with targeted therapies. Cerebrospinal fluid (CSF) analysis of the tumor markers β-human chorionic gonadotrophin (βhCG) and alpha-fetoprotein (αFP) is indicated in certain circumstances; however, it is important to recognize that not all immunoassays have been validated for use in CSF.

Case presentation
=================

A 33-year-old male originally from Brunei presented with acute onset of polydipsia and polyuria. He was consuming 10--12 liters of fluid daily and passing urine hourly overnight. There was no prodrome, no systemic symptoms and normal energy levels and libido. Past history included a left occipital meningioma removed at 17 years of age. He took no regular medications, was a non-smoker and consumed minimal alcohol. There was no personal or family history of connective tissue disorders or malignancy. He had migrated to Australia ten years previously, and immigration health examination, including tuberculosis testing, was normal. He lived with his wife, had no children and worked full-time as a chef.

On examination, he had an elevated body mass index of 30.7, minimal facial hair but Tanner Stage V pubic hair and genital development, a normal adult male voice and reduced testicular volume of 10 mL bilaterally with no palpable masses. Visual fields, cranial and peripheral neurological examinations, were normal. There were no cutaneous features to suggest sarcoidosis (erythema nodosum, cutaneous papules, nodules or plaques), and no enlarged lymph nodes or organomegaly.

Investigation
=============

Initial investigations revealed an elevated serum sodium of 147 mmol/L (reference: 135--145), a raised serum osmolality of 307 mosmol/kg (reference: 278--298) and dilute urine (urine osmol 82 mosmol/kg). A water deprivation test was consistent with central DI. Biochemistry, renal and liver function and full blood examination were normal.

Additional investigations revealed hypogonadotrophic hypogonadism with otherwise intact anterior pituitary function ([Table 1](#tbl1){ref-type="table"}). MRI of the pituitary demonstrated an enhancing, bulbous thickened pituitary stalk with a maximal diameter of 6.2 mm and minor indentation of the inferior optic chiasm ([Fig. 1A](#fig1){ref-type="fig"} and [B](#fig1){ref-type="fig"}). There was no leptomeningeal, dural or cranial nerve enhancement suggestive of CNS lymphoma, neurosarcoidosis or tuberculosis, and no parenchymal lesion to suggest either these diagnoses or solid organ metastases. There was no osseous lesion suggestive of Langerhans cell histiocytosis (punched out lytic lesions or 'geographic skull' on CT, hypointense T1 or gadolinium enhancing lesions on MRI). There was no pineal calcification to suggest intracranial germ cell tumor (GCT); however, other features of GCT on MRI are not specific ([@bib2]).Figure 1MRI brain. (A) Pre- and (B) post-contrast sagittal MRI brain at diagnosis showing thickened, bulbous enhancement of the pituitary stalk which measures 6.2 × 6.0 × 6.2 mm (AP, trans, SI), (C) pre- and (D) post-contrast sagittal MRI brain 6 months after diagnosis, showing reduction in size of the pituitary stalk, now measuring 4.4 × 4.9 × 5.5 mm. Table 1Anterior pituitary function results.ResultAdult male reference rangeFSH (IU/L)\<11--10LH (IU/L)\<11--10Testosterone (nmol/L)1.310--35Prolactin (IU/L)18245--375Early morning cortisol (nmol/L)335145--619ACTH (pmol/L)4.2\<20GH (IU/L)\<1\<7IGF-1 (nmol/L)1311--32TSH (IU/L)1.120.5--4T4 (pmol/L)14.610--19[^1]

Initial investigations to establish the cause of pituitary stalk thickening, including a computed tomography of the chest, abdomen and pelvis, and testicular ultrasound, were unremarkable ([Table 2](#tbl2){ref-type="table"}). Serum tumors markers were normal, including βhCG \<2 IU/L (reference \<2) and αFP 2 μg/L (reference \<10). Quantiferon Gold suggested latent tuberculosis was unlikely. Table 2Specific investigations for the cause of pituitary stalk thickening.ResultAdult male reference rangeSerum βhCG (IU/L)\<2\<2Serum α-FP (µg/L)2\<10PSA (µg/L)0.44≤2.5LD (U/L)401240--480β-2 microglobulin (mg/L)1.5≤2HIV antibody/antigenNot detectedNot detectedIgG4 (g/L)0.130.04--0.86ACE (U/L)28.020.0--70.0Vitamin D (nmol/L)60\>501,25-Dihydroxyvitamin D (pmol/L)11250--19024-h urinary calcium3.4 mmol/24 h2.0--7.5CRP (mg/L)\<1≤10ESR (mm/h)5\<15ANCANegativeNegativeQuantiferon GoldLatent infection unlikelyChest X-rayNormalTesticular ultrasoundReduced testicular volume (8.3 on right and 8.5 mL on left) and vascularity, no lesionsCT chest, abdomen, pelvisNormal[^2]

Given the bulbous appearance of the pituitary stalk on MRI, with no clear diagnosis, the decision was made to perform lumbar puncture for GCT markers (βhCG, αFP), tuberculosis and flow cytometry. This revealed an elevated βhCG level of 11.4 IU/L (reference \<10), with an undetectable αFP level. Gram stain, culture, protein, glucose, cytology, flow cytometry and tuberculosis testing of the CSF were all within normal parameters.

The results of the CSF βhCG raised the possibility of an intracranial GCT. However, the reference range for CSF βhCG has not been well defined. Given the implications of therapy for a GCT, a decision was made to repeat the lumbar puncture prior to considering a pituitary stalk biopsy. Repeat CSF βhCG levels were then performed on various assay instruments and are displayed in [Table 3](#tbl3){ref-type="table"}. Table 3Levels of βhCG in CSF using various immunoassay platform and reference intervals for immunoassay.Assay platformFirst lumbar puncture βhCG (IU/L)Second lumbar puncture βhCG (IU/L)CSF reference interval (IU/L)Siemens Centaur1110\<10Roche CobasNot done\<0.01\<0.70Beckman AccessNot done0.52None availableAbbott ArchitectNot done\<1.2None available

Treatment
=========

Our patient was treated with intranasal desmopressin 10 µg BD with resolution of DI symptoms and was commenced on testosterone transdermal gel. Due to the discordant results of the CSF βhCG levels depending on the assay used, a decision was made to continue monitoring with serial MRI scans. Pituitary stalk biopsy was deferred until there was evidence of progressive stalk thickening.

Outcome and follow-up
=====================

Serial pituitary MRIs performed every two months over a period of six months showed mild reduction in size of the pituitary stalk, from the original size of 6.2 × 6.0 × 6.2 mm (AP, trans, SI) to 4.4 × 4.9 × 5.5 mm ([Fig. 1C](#fig1){ref-type="fig"} and [D](#fig1){ref-type="fig"}). An intracranial GCT was considered less likely based on this, and, based on the absence of features suggesting any alternative cause, a presumptive diagnosis of lymphocytic hypophysitis was made. His DI is persistent and anterior pituitary function remains unchanged.

We plan to monitor his MRI pituitary, pituitary function tests and serum tumor markers every 6 months initially.

Discussion
==========

Our patient presented with typical symptoms of DI and had classical findings on pituitary MRI. A thickened pituitary stalk can be due to neoplastic, inflammatory or congenital causes ([Table 4](#tbl4){ref-type="table"}). The prevalence of etiology differs considerably between reports ([@bib3]). Table 4Causes of, and investigations for, the different causes of pituitary stalk thickening.CategoryCauseInitial investigationsAdditional investigationsNeoplasticGerm cell tumorSerum βhCG, α-FPTesticular US, CSF βhCG and α-FPSolid organ metastases (breast, renal, lung, prostate)CT Chest/abdomen/pelvisCEA, Ca125, Ca19.9, PSACNS lymphomaLDH, β-2 microglobulinHIV screening\
CSF cytology\
Bone marrow aspirate and trephineInflammatory/infectiveLymphocytic hypophysitis\
NeurosarcoidosisIgG4 Calcium, vitamin D, ACE, CXR, 1,25-dihydroxyvitamin D, 24 h urinary calciumLangerhans cell histiocytosisWhole body bone scan, skeletal surveyGranulomatosis with polyangitisCRP, ESR, cANCATuberculosisQuantiferon Gold\
CSF acid fast bacilliWhipple's diseaseCSF *Tropheryma whipplei*CongenitalPituitary hypoplasia\
Pituitary stalk interruption syndrome\
Septooptic dysplasia[^3]

Differentiating between causes requires thorough evaluation. Key features on history include personal and family history of malignancy, connective tissue and autoimmune conditions, constitutional symptoms, respiratory symptoms, travel history and recent pregnancy. Examination should focus on signs of hypopituitarism, cranial nerve deficits, cutaneous changes consistent with sarcoidosis and lymphadenopathy or hepatosplenomegaly, which may suggest malignancy. Initial investigations should encompass the most common causes, with additional specific or invasive investigations based on the clinical picture ([Table 4](#tbl4){ref-type="table"}).

Investigations should also assess pituitary dysfunction, which may result from pituitary stalk thickening. The pituitary stalk transmits vasopressin and oxytocin between the hypothalamus and posterior pituitary, stimulatory hormones to the anterior pituitary and inhibitory factors for prolactin release. Interruption can therefore result in DI, hypopituitarism and hyperprolactinaemia. Studies have demonstrated that 28% of patients with infundibulum lesions have clinical DI, and 32% have at least one anterior pituitary hormone deficit, most commonly hypogonadotrophic hypogonadism, as in our case ([@bib2]).

In this patient, initial investigations did not reveal a diagnosis, and there were no extra-cranial sites to biopsy. CSF analysis should be considered in these patients who are suspected to have, or with risk factors for, central nervous system (CNS) lymphoma, CNS tuberculosis, or intracranial GCT with normal serum αFP and βhCG and a normal testicular ultrasound ([@bib3]).

Non-germinomatous and mixed GCT secrete large amounts of αFP and βhCG; however, pure germinomas may be non-secretory or secrete only low levels of βhCG. The sensitivity and specificity for serum βhCG for diagnosis of GCT varies by cellular type, location (gonadal or extra-gonadal) and stage of disease, but is poor for isolated intracranial tumors ([@bib3], [@bib4]). Elevated serum levels occur in other malignancies, tumor lysis syndrome, primary hypogonadism and precocious puberty. Elevated CSF levels occur in pituitary adenomas, craniopharyngiomas, arachnoidal cysts and Langerhans cell histiocytosis ([@bib5]).

Unfortunately, not all immunoassays for βhCG have been validated for use in CSF, which can make interpretation difficult. Validations of βhCG in CSF using the Roche Diagnostics Elecsys and Siemens Centaur assays have been published ([@bib6], [@bib7]). Other assays may give no reference range or use serum reference intervals as a guide. Given the marked differences between serum and CSF detection limits found on those assays that have been studied in CSF, this is inappropriate.

A validation should include a recovery experiment, reproducibility and the range of values found in healthy individuals as minimum. Ideally, it should also include patients with GCT and other pathologies, to calculate sensitivity and specificity, and a measure of stability and interfering factors. The Roche Diagnostics Elecsys assay for CSF βhCG is stable at any temperature for up to 7 days, and does not appear to be influenced by haemolysis or xanthrochromia; however, similar studies of stability were not performed on the Centaur assay ([@bib6]). Neither study included sufficient patients with GCT to calculate specificity or sensitivity.

The initial CSF βhCG result of 11.4 IU/L in this patient was processed on the Siemens Centaur immunoassay. Mitsios and colleagues evaluated this method for CSF and reported a limit of blank (LoB) of 7.6 IU/L, limit of detection (LoD) of 9.5 IU/L and limit of quantitation (LoQ) of 10 IU/L ([@bib7]). This means that in a specimen containing no βhCG, the reported level may be up to 7.6 IU/L, and the test is unable to reliably differentiate this value from 9.5 IU/L. Standard laboratory practice is to only report values above the LoQ, lower values being reported as '\<10 IU/L'. Hu and colleagues attempted to calculate the sensitivity and specificity of CSF βhCG using the Centaur assay on 58 patients with pathologically confirmed intracranial GCT, 12 patients with Langerhans cell histiocytosis and 5 with other intracranial tumors. They demonstrated that a CSF βhCG of ≥8.2 IU/L had a sensitivity of 47% and specificity of 100% for intracranial GCT ([@bib5]). However, the authors report the LoD of the assay as 2 IU/L, which is the serum not CSF LoD. The final value of 8.2 IU/L is below the LoQ of the assay in CSF, and thus, cannot be reliably used in practice.

Guidelines on the management of intracranial GCT, produced by a panel of experts from the third International Intracranial Germ Cell Tumour symposium in 2013, state that GCT may be diagnosed on the basis of CSF βhCG alone, without histological confirmation, if levels are above nationally defined protocol thresholds ([@bib8]). However, they acknowledge that thresholds for CSF βhCG differ worldwide (\>25--100 IU/L) and do not recommend any particular immunoassay or diagnostic cut-off. Marginal elevations are inadequate alone for diagnosis, and so a pituitary stalk biopsy would be required in our patient for definitive diagnosis.

Pituitary stalk biopsy is invasive and requires specialty neurosurgical expertise and should only be performed if there is no alternative site available for biopsy. It carries a risk of meningitis, CSF leak and permanent panhypopituitarism ([@bib3]). Neurological complications are rare in lesions isolated to the pituitary stalk.

There is no consensus on the indications for pituitary stalk biopsy. Jian and cowokers reviewed 37 patients with DI and pituitary stalk thickening on imaging ([@bib9]). Of idiopathic causes, no patients had pituitary stalk thickening of \>6.5 mm, whereas all cases of GCT were either \>6.5 mm or developed other abnormalities, and only one case of histiocytosis remained \<6.5 mm, at the end of follow-up. A suggested approach therefore is to perform pituitary stalk biopsy if the stalk is above 6.5 mm in size initially or on serial imaging. The authors suggested monitoring for 2 years, as this was the median time for progression; however, a more conservative approach would be to monitor up to 4 years, the upper range for progression.

The majority of intracranial GCT present at 10--21 years of age, with a peak incidence around puberty and higher rates in males and Asian countries ([@bib4]). One-third of patients with germinomas are asymptomatic for six months or more; however, non-germinomatous tumors have a shorter prodrome. They usually affect the midline (suprasellar cistern, pineal gland, fourth ventricle, basal ganglia), but may spread to the hypothalamus and third ventricle or metastasize to the spinal cord, lung or bone. Prognosis varies by cell type -- germinomas are exquisitely radiosensitive and five-year survival rates are \>90%, whereas non-germinomatous tumors have a poorer prognosis and require combination chemoradiotherapy ([@bib4]).

Based on our initial CSF βhCG result, pituitary stalk biopsy was considered; however, the discordant results on repeat testing made us defer this. Serial imaging showed a slight reduction in size, which would be unexpected for a GCT, and so a presumptive diagnosis of lymphocytic hypophysitis was made. Lymphocytic hypophysitis is an inflammatory condition, with infiltration of the pituitary with lymphocytes, and eventual fibrosis. It is more common in females particularly during pregnancy or post-partum, is associated with autoimmune conditions and may be caused by immunotherapy (CTLA4 inhibitors, PD-1 inhibitors) ([@bib10]). MRI shows uniform enhancement without other features ([@bib2]). There are no consensus guidelines on management, and although glucocorticoids may be used, spontaneous resolution is also documented ([@bib10]). Studies of glucocorticoids are limited by low numbers and short duration of follow-up. Given our patient had some reduction in the size of pituitary thickening without active treatment the decision was made not to use glucocorticoids.

Given we have been monitoring our patient for only six months, we cannot definitively exclude a GCT, as new changes may develop over years. However, it would be rare to see a reduction in the pituitary stalk size without treatment for GCT, and so we feel this is less likely. It is important to note that our patient avoided an invasive procedure after the CSF βhCG was repeated using different assays, and as such we would advocate testing CSF tumor markers using more than one analyzer, particularly in the absence of other clinical, biochemical or radiological signs of GCT.

In conclusion, pituitary stalk thickening has multiple causes and requires thorough investigation. In the absence of a diagnosis, and in the right clinical circumstances, CSF analysis should be performed; however, interpretation of results requires knowledge of the specific assays used and validated reference intervals for this. Pituitary stalk biopsy should be considered where the stalk measures \>6.5 mm or other imaging abnormalities are present and sufficient neurosurgical expertise is available.
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[^1]: ACTH, adrenocorticotrophic hormone; FSH, follicular-stimulating hormone; GH, growth hormone; IGF-1, insulin-like growth factor 1; LH, luteinizing hormone; T4, thyroxine; TSH, thyroid-stimulating hormone.

[^2]: α-FP, alpha-fetoprotein; βhCG, human chorionic gonadotrophin; ACE, angiotensin converting enzyme; ANCA, antineutrophil cytoplasmic antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HIV, human immunodeficiency virus; IgG4, immunoglobulin G subtype 4; LD, lactate dehydrogenase; PSA, prostate specific antigen.

[^3]: α-FP, alpha-fetoprotein; ACE, angiotensin-converting enzyme; ANCA, antineutrophil cytoplasmic antibody; Ca125, cancer antigen 125; Ca19.9, cancer antigen 19.9; CEA, carcinoembryonic antigen; CNS, central nervous system; CRP, C-reactive protein; CSF, cerebrospinal fluid; CT, computed tomography; CXR, chest X-ray; ESR, erythrocyte sedimentation rate; hCG, human chorionic gonadotrophin; HIV, human immunodeficiency virus; IgG4, immunoglobulin G version 4; LDH, lactate dehydrogenase; PSA, prostate specific antigen; US, ultrasound.
